

Supplementary Table 1 Preoperative characteristics for grade I internal hemorrhoids

Subgroup	Gender (female/male)	Age (years, mean $\pm$ SD)	Disease duration [months, M (Q1, Q3)]	BMI (kg/m ² , mean $\pm$ SD)
ERBL	5/17	50.32 $\pm$ 12.56	12.00(1.75,36.00)	24.03 $\pm$ 3.21
IS	7/18	51.52 $\pm$ 13.49	12.00(1.5,36.00)	23.80 $\pm$ 2.87
ESB	5/9	54.43 $\pm$ 11.07	4.00(0.29,88.50)	24.29 $\pm$ 3.24
Total	17/44	51.75 $\pm$ 12.53	12.00(1.00,36.00)	23.99 $\pm$ 3.03
Statistic	$\chi^2 = 0.718$	$F = 0.459$	$H = 0.141$	$F = 0.116$
<i>P</i>	0.698	0.634	0.932	0.890

ERBL: endoscopic rubber band ligation, IS: injection sclerotherapy, ESB: endoscopic polidocanol sclerobanding, BMI: body mass index.

Supplementary Table 2 Treatment data for grade I internal hemorrhoids

Subgroup	Rubber bands [number, M (Q1, Q3)]	Sclerosant dosage [mL, M (Q1, Q3)]	Anesthesia method (local/intravenous anesthesia)	Follow-up duration [months, M (Q1, Q3)]
ERBL	4.00(3.00,5.00)	-	12/10	24.00(11.63,24.00)
IS	-	10.00(6.50,10.00)	17/8	24.00(14.00,24.00)
ESB	4.00(3.00,4.25)	8.00(5.00,10.00)	7/7	24.00(15.00,24.00)
Total	4.00(3.00,5.00)	10.00(6.00,10.00)	36/25	24.00(14.25,24.00)
Statistic	$Z = -0.204$	$Z = -0.720$	$\chi^2 = 1.487$	$H = 0.737$

<i>P</i>	0.838	0.472	0.476	0.692
----------	-------	-------	-------	-------

ERBL: endoscopic rubber band ligation, *IS*: injection sclerotherapy, *ESB*: endoscopic polidocanol sclerobanding.

Supplementary Table 3 Preoperative characteristics for grade II-III internal hemorrhoids

Subgroup	Gender (female/male)	Age (years, mean ± SD)	Disease duration [months, (Q1, Q3)]	BMI (kg/m ² , mean ± SD)	Hemorrhoid grade (number, %)	
					II	grade III
ERBL	21/27	48.40 ± 11.21	42.00(12.00,79.50)	24.66 ± 3.27	22(45.83)	26(54.17)
IS	12/29	49.98 ± 12.34	48.00(35.50,120.00)	23.46 ± 2.35	22(53.66)	19(46.34)
ESB	25/26	50.00 ± 12.93	60.00(24.00,120.00)	24.55 ± 2.99	21(41.18)	30(58.82)
Total	58/82	49.15 ± 12.12	48.00(24.00,120.00)	24.27 ± 2.95	65(46.43)	75(53.57)
Statistic	$\chi^2 = 3.816$	$F = 0.220$	$H = 4.481$	$F = 2.215$	$H = 1.424$	
<i>P</i>	0.148	0.803	0.106	0.113	0.491	

ERBL: endoscopic rubber band ligation, *IS*: injection sclerotherapy, *ESB*: endoscopic polidocanol sclerobanding, *BMI*: body mass index.

Supplementary Table 4 Treatment data for grade II-III internal hemorrhoids

Subgroup	Rubber bands	Sclerosant dosage	Anesthesia method	Follow-up duration
p	[number, M (Q1, Q3)]	[mL, M (Q1, Q3)]	(local/intravenous anesthesia)	[months, M (Q1, Q3)]
ERBL	5.00(3.00,5.75)	-	30/18	17.50(8.63,24.00)
IS	-	8.00(7.00,10.00)	25/16	16.00(12.00,24.00)
ESB	4.00(3.00,5.00)	8.00(6.00,10.00)	38/13	17.50(10.00,24.00)
Total	4.00(3.00,5.00)	8.00(6.00,10.00)	93/47	17.25(10.63,24.00)
Statistic	Z = -1.284	Z = -1.202	$\chi^2 = 2.372$	H = 0.633
P	0.199	0.229	0.305	0.729

ERBL: endoscopic rubber band ligation, IS: injection sclerotherapy, ESB: endoscopic polidocanol sclerobanding.